SINOVAC BIOTECH LTD Logo

SINOVAC BIOTECH LTD

Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.

SVA | US

Overview

Corporate Details

ISIN(s):
AGP8696W1045
LEI:
Country:
United States of America
Address:
NO. 39 SHANGDI XI ROAD, 100085 BEIJING
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sinovac Biotech Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company's commercialized product portfolio includes vaccines for COVID-19 (CoronaVac®), hepatitis A (Healive®), combined hepatitis A and B (Bilive®), influenza, enterovirus 71 (Inlive®), polio, pneumonia, and chickenpox. Sinovac has achieved significant milestones, including developing a globally pioneered EV71 vaccine and China's only independently developed Hepatitis A and B combination vaccine. Several of its products have received World Health Organization (WHO) prequalification, and its CoronaVac® vaccine is included in the WHO's Emergency Use Listing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all SINOVAC BIOTECH LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SINOVAC BIOTECH LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SINOVAC BIOTECH LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.